Submission on the National Food Security Strategy Discussion Paper
Policy & Practice Report
WHO’s draft Global Plan of Action for the Health of Indigenous Peoples
Policy & Practice Report
Evaluating the impact, investment case and scale-up of ‘Health Promoting Schools’ in Fiji
BackgroundIn 2016, Health Promoting Schools (HPS) under the Fiji School Health Policy was launched as a joint program by the Ministry of Health and Medical Services and the Ministry of Education of Fiji. This is a ‘whole of school’ approach to improving health and wellbeing of Fiji’s children and youth by incorporating into the school curriculum resources to improve awareness and competency in promoting healthy behaviours. It has three key areas of focus: 1) diet and physical activity; 2) water, sanitation, and hygiene (WASH); and 3) mental health and wellbeing. In this initial phase of implementation, with support from the World Health Organization (WHO) and the Korean International Cooperation Agency (KOICA), HPS was delivered in 285 primary (ages 6-14 years, grades 1-8) and secondary schools (ages 14-18 years, grades 9-12).There has been limited evaluation of the HPS program with important issues as yet answered: how the HPS program is being used across the participating schools, whether the program
RESist-NCD: Building resilient and people-centred health systems for non-communicable disease prevention and control in Pacific and Southeast Asian countries
The RESist-NCD Partnership
RESist-NCD comprises a comprehensive four-year program of work (2024-2028) to support governments in Fiji, Papua New Guinea, the Philippines, Vietnam and Cambodia to develop interventions for the prevention and early treatment of diabetes and hypertension (a key cardiovascular disease risk factor). The RESist-NCD consortium includes: The George Institute for Global Health; UNSW, Sydney; and the Clinton Health Access Initiative (CHAI), and embeds strong partnership with relevant interest-holders in governments, health services, academic institutions, civil society organisations, communities and international agencies in the RESist-NCD partner countries.
The RESist-NCD program is addressing crucial gaps in NCD policy implementation through three integrated workstreams that take a whole systems approach. Our program will not only strengthen high quality, equitable diabetes and hypertension prevention, screening and management services integrated with primary health care
Shop-to-Stop Hypertension: A public screening campaign to detect and manage raised blood pressure in Australian adults
Background
Worldwide the leading risk factor for death is raised blood pressure (BP), accounting for ~30,000 deaths daily.1 In Australia, high BP is responsible for 43% of coronary heart disease, 41% of stroke, 65% of the burden of hypertensive heart disease, 38% of chronic kidney disease, 32% of atrial fibrillation and flutter and 3.6% of dementia.2 Better BP control could save more lives than any other single treatment intervention.3 In Australia, BP control rates have stagnated since 2011 at ~32%,4, 5 leading to a 2022 call to action to improve uncontrolled BP in Australia.5
Hypertension (the condition you have from high BP) is called the "silent killer" because most people who have raised BP do not have any symptoms.6 In Australia, 34% of adults have hypertension,4 but millions remain unaware and undiagnosed.6, 7 Only one in two people detected to have high BP are aware of their condition.8 Innovative strategies to target wider and high-risk populations,
PREVENTion with SGLT-2 inhibition of Acute Kidney Injury in intensive care (PREVENTS-AKI)
Background
Acute Kidney Injury (AKI) affects up to 1 in 2 patients treated in the ICU, and is associated with poorer survival, reductions in long term kidney function and greater cost of treatment. There are no treatments proven to reduce these impacts of AKI but there is a growing evidence base suggesting that inhibitors of the sodium-glucose transport protein 2 (SGLT-2 inhibitors) in the kidney tubule may protect against AKI.
SGLT-2 inhibitors were originally developed as a treatment for type 2 diabetes but have been proven in recent clinical trials to significantly improve outcomes for patients with heart disease and/or kidney impairment - with fewer patients progressing to dialysis, needing hospital care or dying. Later examination of these trials has also shown lower rates of AKI in participants receiving SGLT-2 treatment but, as these results were not the main outcome of the studies, these findings are not enough to change patient treatment.
Aim
To conduct a prospective, multi-centre, parall
The wider benefits of SGLT2 inhibitors
Policy & Practice Report
Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)
Current status– finished recruitment – in follow-up.TRIDENT is an international medical research study which aims to determine the effect of more intensive blood pressure control to prevent recurrent stroke in patients who have had an intracerebral haemorrhage (ICH) (a stroke caused by ruptured blood vessel in the brain). The aim of this project is to test the superiority of a fixed low-dose combination blood pressure-lowering pill (Triple Pill) strategy in recurrent stroke in patients with a history of ICH.Acute ICH accounts for at least 10% of the 20 million new strokes in the world each year. ICH survivors are at high risk of recurrent stroke and other serious cardiovascular events. Numerous studies have proven the benefit of stroke survivors reducing their risk of recurrent stroke through taking blood pressure-lowering medications. However, studies have shown that many ICH survivors are either not receiving any blood pressure-lowering medication or they are receiving inadequate control.The TRIDENT stu
The TReAT trial: Mobile application for rehabilitation support after knee replacement
Background
Knee replacement improves the quality of life for those suffering from disabling knee osteoarthritis. Physiotherapy is an important component of the rehabilitation phase following surgery for restoring function and improving quality of life. However, poor adherence to physical therapy due to various socio-environmental and patient-related factors delays recovery. A lack of mechanism for the continuum of care following discharge to home leads to sub-optimal outcomes, chronic knee pain and patient dissatisfaction in some proportions of individuals.
Evidence suggests that home-based physical rehabilitation with a monitoring mechanism is as good as and cost-effective compared to clinic-based rehabilitation. In India, unsupervised home-based rehabilitation is the usual care, leading to a considerable amount of out-of-pocket expenditure to seek physiotherapist support at home. Hence, keeping the local requirements and literacy level in mind, a customised and context-specific rehabilitation monitori
REVERSE: Reducing cardiovascular and kidney risk in diabetes
Background
Diabetes is a major public health challenge, causing additional complications across multiple organ systems. Cardiovascular disease (CVD) and chronic kidney disease (CKD) are the leading causes of disability and death in people with type 2 diabetes mellitus (T2DM).
In Australia, T2DM prevalence has nearly tripled in recent decades, with around 1.3 million people affected. The condition carries enormous economic and societal costs. T2DM has a major impact in socioeconomically disadvantaged areas like Western Sydney, South-Western Sydney, and regional NSW, where high prevalence and CVD/CKD complications represent major challenges for local health services.
Treatments to slow and prevent the CVD/CKD effects of diabetes exist, but they rely on a health system that can readily identify high-risk patients, implement, and monitor treatment, and coordinate the complex care of such patients. Although proven strategies to delay and prevent the impacts of CVD and CKD in high-risk diabet
Assessment of absolute cardiovascular disease risk
Policy & Practice Report
Evidence library
Please find below a list of the key publications supporting the case for potassium-enriched salt. For a more comprehensive list, click here or to return to the main page click here.
Trials
Effect of Salt Substitution on Cardiovascular Events and Death.New England Journal of Medicine, 2021https://www.nejm.org/doi/full/10.1056/nejmoa2105675
Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial.Nature Medicine, 2023https://www.nature.com/articles/s41591-023-02286-8
Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis.Heart 2022https://heart.bmj.com/content/108/20/1608.long
Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trialThe American Journal of Clinical Nutrition, 2021https://www.sciencedirect.com/science/article/pii/S0002916522003185